138 related articles for article (PubMed ID: 32886897)
41. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
42.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
43. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
44. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
[TBL] [Abstract][Full Text] [Related]
45. ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A; Dygai-Cochet I; Riedinger JM; Humbert O; Berriolo-Riedinger A; Toubeau M; Guiu S; Coutant C; Coudert B; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):428-37. PubMed ID: 24196916
[TBL] [Abstract][Full Text] [Related]
46. Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associé à La Grossesse) network.
Despierres M; Boudy AS; Selleret L; Gligorov J; Richard S; Thomassin I; Dabi Y; Zilberman S; Touboul C; Montravers F; Khaldoun K; Darai E
Acta Oncol; 2022 Mar; 61(3):302-308. PubMed ID: 34779355
[TBL] [Abstract][Full Text] [Related]
47. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
[TBL] [Abstract][Full Text] [Related]
48. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
49. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
51. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
52. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
[TBL] [Abstract][Full Text] [Related]
53. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review.
Patel MM; Le-Petross HT
Chin Clin Oncol; 2021 Dec; 10(6):56. PubMed ID: 34806397
[TBL] [Abstract][Full Text] [Related]
54. Positron emission tomography in staging early lung cancer: a randomized trial.
Maziak DE; Darling GE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Miller JD; Gu CS; Cline KJ; Evans WK; Levine MN
Ann Intern Med; 2009 Aug; 151(4):221-8, W-48. PubMed ID: 19581636
[TBL] [Abstract][Full Text] [Related]
55. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
[TBL] [Abstract][Full Text] [Related]
56. Bone Marrow Metastasis Is an Early Stage of Bone Metastasis in Breast Cancer Detected Clinically by F18-FDG-PET/CT Imaging.
Al-Muqbel KM
Biomed Res Int; 2017; 2017():9852632. PubMed ID: 28884133
[TBL] [Abstract][Full Text] [Related]
57. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Kaji Y; Fukasawa I; Inaba N; Sugimura K
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1912-20. PubMed ID: 18682935
[TBL] [Abstract][Full Text] [Related]
59. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
60. Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?
Signorelli M; Guerra L; Montanelli L; Crivellaro C; Buda A; Dell'Anna T; Picchio M; Milani R; Fruscio R; Messa C
Gynecol Oncol; 2011 Nov; 123(2):236-40. PubMed ID: 21855972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
